Fentanyl Patch Useful Alternative in Cancer Pain Patients
November 1st 1996ROCHESTER, Minn-Use of transdermal fentanyl (Duragesic) in ambulatory cancer pain patients appears to be safe and effective, Julie E. Hammack, MD, and her colleagues from four North Central Cancer Treatment Group (NCCTG) institutions report.
Analysis of Microvessel Density Predicts Extraprostatic Spread
November 1st 1996HOUSTON-A new automated computerized system for analyzing the microvessel density of prostate tumors may help physicians more accurately stage the cancer before surgery, and thus assist physicians and patients in making treatment decisions, say Brian J. Miles, MD, of Baylor College of Medicine, and his colleagues at the Mayo Clinic, Washington University, Laval University, Quebec, University of Colorado, and Fred Hutchinson Cancer Research Center.
Late Infection With Cytomegalovirus a Serious Problem in Bone Marrow Transplant Patients
November 1st 1996NEW ORLEANS--Ganciclovir (Cytovene) protects allogeneic bone marrow transplant (BMT) recipients in the early postoperative period, but late infection with cytomegalovirus (CMV) continues to cause serious problems, Helen C. Maltezou, MD, reported at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
FDA Panel Cancels HIV Drug Meeting
November 1st 1996ROCKVILLE, Md-The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.
Foundation Supports Legislation Backing Cancer Treatment Coverage
November 1st 1996NEWPORT NEWS, Va-A new organization, the National Patient Advocate Foundation (NPAF), has been created to support bills favoring patient access to insurance funding and encourage legislation on issues that threaten cancer patients' coverage for evolving therapies, therapeutic devices, or agents prescribed by their treating physicians.
Antibiotic Monitoring Programs Can Avert Potential Errors in Prescribing
November 1st 1996NEW ORLEANS--Monitoring programs in which hospital pharmacists double-check physicians' orders for antibiotics are proving effective in averting potential problems of safety or efficacy, researchers reported at the 36th Inter-science Conference on Antimicrobials and Chemotherapy (ICAAC).
Government's Investment in Visible Human Project Begins to Pay Dividends in Oncology
November 1st 1996BETHESDA, Md-The Visible Human Project has become a virtual reality beyond the expectations of many. Already, researchers are experimenting with the computerized anatomies of a man and woman, seeking ways to use them to the benefit of medical education, diagnostics, and surgery.
'Consolidation Inevitable' in Oncology Practice
November 1st 1996ORLANDO-"Even with 1.2 million new cancer cases diagnosed each year, 4.5 million cancer patients, and cancer the costliest disease, there are still more oncologists out there than we need," said Harold Wodinsky, vice president of managed care and network development for EquiMed, Inc., a national multispecialty physician practice management firm.
SGO Researchers Urge Special Treatment of Atypical Glandular Cells Found in Pap Smears
November 1st 1996A typical glandular cells detected on cervical Pap smears indicate significant cervical pathology in 17% of cases and require an immediate work-up and biopsy, according to research reported in the October issue of Gynecologic Oncology, the scientific publication of the Society of Gynecologic Oncologists (SGO).
Tuberculosis Cases in Cancer Patients Traced to BCG-Contaminated Catheters
November 1st 1996NEW ORLEANS-Beware the juxtaposition of BCG (Bacillus Calmette and Guérin) and other chemotherapeutic agents. Four patients in the same oncology outpatient clinic in Barcelona, Spain, developed disseminated BCG infection around the same time, apparently due to BCG-contaminated intravenous catheters, Dr. Javier Garau reported at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Low-Dose Liposomal Amphotericin Effective in Aspergillosis
November 1st 1996NEW ORLEANS-High doses of liposomal amphotericin B are no more effective than low doses in the treatment of invasive aspergillosis in neutropenic patients, European researchers reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Resonance Energy Transfer Assay Measures HIV-1 Fusion
November 1st 1996TARRYTOWN, NY--An essential step in the life cycle of HIV is entry into the cell, allowing delivery of the viral genetic information to the target cell cytoplasm. Attachment and fusion are the critical events that make this possible.
Purging Technique Increases Survival in Autologous BMT Patients
November 1st 1996Researchers report that depleting bone marrow of contaminating malignant cells with anticancer drugs prior to transplantation (purging) may increase long-term survival in certain leukemia patients. This was the conclusion of a comparative study of purged vs nonpurged marrow in patients with acute myelogenous leukemia (AML). The findings were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Marketing Package Essential for Success of Oncology Network
November 1st 1996ORLANDO--More physicians are electing to form specialty networks to contract with health care payers, and professional marketing of these alliances to health plans is critical to their economic survival, said Howard Fagin, PhD, of Physician's Health Corporation, an Atlanta-based company that helps physicians organize single and multispecialty networks.
Americans Split on Physician-Assisted Suicide, Support Hospice
November 1st 1996NEW YORK--A recent Gallup opinion poll shows that Americans are split on the issue of legalizing physician-assisted suicide, but strongly favor hospice care. In the survey of 1,007 respondents, age 18 and over, 70% said they would seek hospice care for themselves if they were terminally ill. Half of the respondents said they favored legalizing physician-assisted suicide, but only 35% said they would choose it for themselves if they became terminally ill.
NIDR and NCI Establish Four Research Centers for Oral Cancer
November 1st 1996BETHESDA, Md-With the aim of increasing oral cancer survival rates, the National Institute of Dental Research (NIDR) and the National Cancer Institute will jointly fund four research centers to investigate the causes of oral cancers and to develop improved treatments.
Folate: Effects on Carcinogenesis and the Potential For Cancer Chemoprevention
November 1st 1996A provocative array of observations from both laboratory and clinical investigations indicates that alterations in folate status modulate the process of neoplastic transformation in selected epithelial tissues. Diminished folate
Parents of Childhood Cancer Survivors May Show Symptoms of Post-Traumatic Stress
November 1st 1996BUFFALO, NY--While most long-term survivors of childhood cancer suffer few psychological scars, up to 30% of fathers and 40% of mothers may exhibit moderate to severe symptoms of post-traumatic stress (PTS)--a disorder commonly associated with war veterans and victims of violent crime.
En Acción Public Service Ads Target Hispanics
November 1st 1996SAN ANTONIO--A number of Hispanic notables, including Olympic gold medalist Pablo Morales and actors Maria Conchita Alonso and Jesse Borrego, have recorded public service announcements aimed at Hispanics encouraging cancer screening, good nutrition, exercise, not smoking, and sun protection.
Community Oncologists Have Number of Options in Responding to Managed Care
November 1st 1996ORLANDO-Community oncologists have a number of options in attempting to maximize their position in the managed care environment, said Myron H. Goldsmith, MD, executive director of development for the City of Hope Oncology Network, Los Angeles.
BOOK REVIEW: Changing the Odds: Cancer Prevention Through Personal Choice and Public Policy
October 1st 1996The premise of Steen's book is that nearly everyone is confused about cancer prevention. The public, for whom the book is written, is the most confused, but cannot be faulted. According to Steen, the responsibility for their confusion lies with scientists and the press. Scientists make mistakes by reporting preliminary data from inadequate and mostly "workmanlike, undistinguished" (page 3) studies. The press, in turn, repeats these mistakes, adds some of its own, and so oversimplifies a complex topic that the public, in the end, receives "unconnected facts, partial truths, and outright lies" (page 3).
Roxane HIV-Pain Scholars at Hopkins
October 1st 1996COLUMBUS, Ohio--Roxane Laboratories has announced that Johns Hopkins University School of Medicine will implement the Roxane HIV-Pain Scholars program to train physicians, nurses, and pharmacists to treat and manage HIV-related peripheral nerve pain.
Six Factors Influence Long-Term Brain Cancer Survival
October 1st 1996TAMPA, Fla--The average brain tumor patient survives just 1 year after diagnosis, so long-term survival, defined as living at least 100% longer than the median survival of historical controls, is especially remarkable. Previous studies have shown that only 7% to 10% of brain cancer patients survive long-term.
In Some Cases, Tests Show False HIV Antibody Response
October 1st 1996VANCOUVER, BC--AIDS test results are not always what they seem, and current vaccine research may be headed in the wrong direction, Luc Montagnier, MD, said at the 11th International Conference on AIDS. Dr. Montagnier, of the Institut Pasteur, is a co-discoverer of HIV-1, the AIDS virus.
Klausner Tells NCAB About Bypass Budget, Plans for HPV Vaccine
October 1st 1996BETHESDA, Md--Planning for science is "oxymoronic," because you can't plan for results, NCI Director Richard Klausner told the National Cancer Advisory Board (NCAB). "Instead, you have to plan for facilitating large-scale thinking," he said.